"10.1371_journal.pone.0140995","plos one","2015-10-23T00:00:00Z","Caroline J Jolley; James Bell; Gerrard F Rafferty; John Moxham; John Strang","Division of Asthma, Allergy and Lung Biology, Faculty of Life Sciences and Medicine, King’s College London, King’s Health Partners, Denmark Hill, London, United Kingdom; National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, King’s Health Partners, Denmark Hill, London, United Kingdom; Addictions Services, South London & Maudsley NHS Foundation Trust, King’s Health Partners, Denmark Hill, London, United Kingdom","Conceived and designed the experiments: JB JS. Performed the experiments: CJJ. Analyzed the data: CJJ. Contributed reagents/materials/analysis tools: CJJ JS GFR JM JB. Wrote the paper: CJJ JS GFR JM JB.","We have read the journal's policy and the authors of this manuscript have the following competing interests. JS is a researcher and clinician and has worked with a range of types of treatment and rehabilitation service-providers. He has contributed to the work of a range of governmental and non-governmental organisations and has received project grant support and/or honoraria and/or consultancy payments from Department of Health, NTA (National Treatment Agency), PHE (Public Health England), Home Office, NICE (National Institute for Health and Clinical Excellence), and EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) as well as research grants from (last 3 years) NIHR (National Institute on Health Research), MRC (Medical Research Council) and Pilgrim Trust. He has also worked with pharmaceutical companies to seek to identify new or improved treatments (including, last 3 years, Martindale, Reckitt-Benkiser, Lundbeck, MundiPharma, Viropharma, Rusan/iGen) and he and his employer (King’s College London) have received honoraria, travel costs and/or consultancy payments. His employer (King’s College London) is registering intellectual property on a novel buccal naloxone (with which JS is involved), and JS has also been named in a patent registration by a Pharma company (declared above) as inventor of a potential concentrated naloxone nasal formulation. A fuller account of JS’s interests is given on his personal web-page of the Addictions Department of King's College London at http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx. JB has held consultancy agreements with Reckitt-Benkiser, Britannia pharmaceuticals and Martindale Pharma, and is PI on research grants funded by Reckitt-Benkiser and Martindale Pharma. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2015","10","Caroline J Jolley","CJJ",5,TRUE,2,1,1,5,TRUE,TRUE,FALSE,0,NA,FALSE
